Daily Sepsis Research Analysis
Three impactful sepsis studies stand out today: a randomized trial shows vitamin A supplementation does not shorten ICU stay or reduce 28-day mortality in pediatric sepsis; a national Vietnamese hospital survey quantifies the heavy burden of carbapenem-resistant Gram-negative infections with higher mortality, longer stays, and costs; and a large ICU database analysis links persistently high serum phosphate trajectories to greater 28-day mortality in high-risk Cardiovascular-Kidney-Metabolic seps
Summary
Three impactful sepsis studies stand out today: a randomized trial shows vitamin A supplementation does not shorten ICU stay or reduce 28-day mortality in pediatric sepsis; a national Vietnamese hospital survey quantifies the heavy burden of carbapenem-resistant Gram-negative infections with higher mortality, longer stays, and costs; and a large ICU database analysis links persistently high serum phosphate trajectories to greater 28-day mortality in high-risk Cardiovascular-Kidney-Metabolic sepsis phenotypes.
Research Themes
- Pediatric sepsis nutrition and negative RCT evidence
- Antimicrobial resistance burden and infection prevention gaps
- Metabolic phenotyping and prognostic trajectories in sepsis
Selected Articles
1. A randomized controlled trial on the efficacy and safety of vitamin A supplementation in children with sepsis.
In a single-center randomized, single-blind trial of 156 children with sepsis, vitamin A supplementation did not reduce ICU length of stay or 28-day mortality compared with placebo. Exploratory signals suggest possible benefits on systemic inflammation and lactate metabolism, warranting further study, particularly regarding interactions with albumin.
Impact: This registered RCT provides high-quality negative evidence against routine vitamin A supplementation in pediatric sepsis, refining clinical practice and research priorities.
Clinical Implications: Routine vitamin A supplementation should not be adopted to shorten ICU stay or reduce mortality in pediatric sepsis; consider targeted trials in deficient subgroups and mechanistic studies on inflammation and lactate-albumin interactions.
Key Findings
- Randomization of 156 children with sepsis (VAS n=72, placebo n=84).
- No significant reduction in ICU length of stay with vitamin A supplementation.
- No improvement in 28-day mortality with vitamin A versus placebo.
- Exploratory signals suggest potential benefits on systemic inflammation and lactate metabolism.
- Trial was registered (NCT04127968), supporting methodological rigor.
Methodological Strengths
- Randomized, controlled, registered clinical trial design
- Predefined primary and secondary outcomes with clinically meaningful endpoints
Limitations
- Single-center, single-blind design limits generalizability and may introduce performance bias
- Sample size may be underpowered for mortality differences and subgroup analyses by vitamin A deficiency
Future Directions: Conduct multicenter, adequately powered RCTs targeting vitamin A–deficient subgroups, and mechanistic studies clarifying VA–albumin interactions and impacts on inflammatory and metabolic pathways.
BACKGROUND: Our previous research confirmed that vitamin A (VA) deficiency commonly occurs in children with sepsis, and serum VA levels negatively correlate with disease severity. This study aimed to evaluate the efficacy and safety of VA supplementation (VAS) in children with sepsis. METHODS: A randomized, single-blind, single-center trial was conducted from June 2020 to March 2024 involving children diagnosed with sepsis. Participants were randomly allocated to either the VAS group or the placebo group. The primary outcome was length of stay in the ICU, and secondary outcomes included hospital length of stay, 28-day mortality, duration of mechanical ventilation, and antibiotic usage. Vital signs, clinical symptoms, and laboratory data were recorded, and statistical analyses assessed the efficacy and safety of VAS. RESULTS: A total of 156 children with sepsis were enrolled: 72 in the VAS group and 84 in the placebo group. The median baseline VA level among participants was 147.22 (97.20-258.04) ng/ml. There was no significant difference in ICU length of stay between the VAS and placebo groups [14 (7-27) vs. 16.5 (9.3-26) days, CONCLUSIONS: VAS did not significantly reduce ICU length of stay or 28-day mortality in children with septic shock, however, it may have beneficial effects on systemic inflammation and lactate metabolism. Further studies are warranted to explore the relationship between VA and ALB. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, identifier NCT04127968.
2. Burden of carbapenem-resistant Gram-negative bacterial infections in Vietnam: a national hospital survey.
Across 324 hospitals in Vietnam, 30.2% of 57,667 Gram-negative isolates were carbapenem-resistant, with CRE, CRAB, and CRPA contributing substantially. CRE infections were associated with higher crude mortality (31.7% vs 20.2%), longer stays, and increased costs; microbiology capacity and IPC implementation varied widely.
Impact: This national snapshot quantifies the clinical and economic burden of CRGNB and highlights gaps in laboratory capacity and IPC, directly informing policy and resource allocation in LMIC settings.
Clinical Implications: Strengthen microbiology infrastructure, expand CRGNB screening, and implement standardized IPC bundles to reduce mortality and costs; inform antimicrobial stewardship and empiric therapy for CRE sepsis.
Key Findings
- Among 57,667 Gram-negative isolates, 30.2% (17,417) were carbapenem-resistant.
- CRE infections had higher crude mortality (31.7% vs 20.2%), longer stays (10.4 vs 8.9 days), and higher costs (1025 vs 773).
- Only about half of hospitals reported capacity for culture and susceptibility testing.
- IPC activities were limited (CRE surveillance 41%, isolation 36%, point prevalence surveys 15%, cohort care 7%).
Methodological Strengths
- Nationwide, multi-level hospital participation with large isolate count
- Comparative outcome metrics (mortality, LOS, cost) between resistant and susceptible infections
Limitations
- Self-reported survey data without patient-level risk adjustment may introduce reporting and selection biases
- Cross-sectional design limits causal inference and temporal trend assessment
Future Directions: Establish standardized national surveillance with patient-level data, strengthen lab capacity, evaluate IPC bundle effectiveness, and assess cost-effectiveness of stewardship and screening programs.
INTRODUCTION: The World Health Organization Bacterial Pathogen Priority List 2024 highlights carbapenem-resistant Gram-negative bacteria (CRGNB), including Enterobacterales (CRE), Acinetobacter baumannii (CRAB) and Pseudomonas aeruginosa (CRPA), as top priorities due to their virulence, resistance, transmission and limited treatment options. OBJECTIVE: This national hospital survey aimed to assess the burden of CRGNB infections and evaluate microbiological laboratory capacity across Vietnam. METHODS: An online survey was distributed to central hospitals and provincial departments of health in the 63 provinces of Vietnam, which then forwarded it to district and private hospitals. RESULTS: In total, 324 hospitals participated in this study: 20 central hospitals, 190 provincial hospitals, 106 district hospitals and eight private hospitals. Half reported microbiological capacity for bacterial culture and susceptibility testing. Among 57,667 reported Gram-negative isolates, 17,417 (30.2%) were CRGNB, including Klebsiella pneumoniae (CRE 37%), Escherichia coli (CRE 11%), A. baumannii (CRAB 64%) and P. aeruginosa (CRPA 39%). CRE sepsis treatment included cephalosporins, aminoglycosides, carbapenems, fluoroquinolones and colistin. CRE infections were associated with higher crude mortality rates (31.7% vs 20.2%; P<0.001), longer hospital stays (10.4 vs 8.9 days; P<0.001), and higher costs (1025 vs 773; P<0.001) compared with carbapenem-susceptible Enterobacterales. Reported infection prevention and control (IPC) interventions included CRE surveillance (41%), isolation (36%), point prevalence surveys (15%), and cohort care (7%). IPC funding sources included general health insurance (40%) and hospital funds (32%). CONCLUSION: CRGNB pose a significant burden in terms of morbidity, mortality and financial impact. There is an urgent need to strengthen the microbiological infrastructure, improve CRGNB screening, and enhance IPC measures.
3. Targeting serum phosphate trajectory stratification to improve outcomes in high-risk Cardiovascular-Kidney-Metabolic-Sepsis cohorts.
Using MIMIC-IV, investigators identified serum phosphate trajectory patterns over the first 7 ICU days in high-risk CKM-sepsis patients. Persistently high phosphate trajectories were associated with markedly higher 28-day mortality (OR 2.909), especially among younger and male patients, suggesting actionable metabolic risk stratification.
Impact: Introduces trajectory-based metabolic phenotyping linked to mortality in high-risk CKM-sepsis, using robust causal-inference methods, pointing to phosphate as a modifiable target.
Clinical Implications: Consider integrating serum phosphate trajectory monitoring into ICU analytics for high-risk CKM-sepsis patients and testing phosphate-lowering strategies in targeted trials.
Key Findings
- Unsupervised clustering identified four metabolic phenotypes and distinct 7-day ICU phosphate trajectories.
- Persistently high phosphate trajectory (Group 3) was associated with higher 28-day mortality (OR=2.909; p<0.001).
- Risk elevation was more pronounced in patients <65 years and in males.
- Associations were robust across multivariable models, IPW, and doubly robust estimation.
Methodological Strengths
- Use of large, granular ICU database (MIMIC-IV) with daily laboratory trajectories
- Robust statistical approach including IPW and doubly robust estimation with subgroup analyses
Limitations
- Observational design limits causal inference; residual confounding may persist
- External validation and interventional studies targeting phosphate are needed
Future Directions: Prospective validation in multi-center cohorts and randomized trials of phosphate-modulating interventions in identified high-risk phenotypes.
BACKGROUND: Sepsis patients exhibit complex clinical conditions, frequently complicated with metabolic dysregulation. Cardiovascular-Kidney-Metabolic Syndrome (C-K-M) is classified as below: stage 0, no C-K-M risk factors; stage 1, excess or dysfunctional adiposity; stage 2, metabolic risk factors (hypertriglyceridemia, hypertension, diabetes, metabolic syndrome) or moderate- to high-risk chronic kidney disease; stage 3, subclinical cardiovascular diseases (CVD) in C-K-M syndrome or risk equivalents (high predicted CVD risk or very high-risk chronic kidney diseases); and stage 4, clinical CVD in C-K-M syndrome. While high-risk patients defined by C-K-M criteria often have poor outcomes, studies seldom have classified these patients into subtypes based on metabolic profiles. Serum phosphate, recently recognized as a potential metabolic and organ function marker, has unclear dynamic trajectories and prognostic significance across high-risk CKM-sepsis subgroups. PURPOSE: This study aimed to evaluate the association between serum phosphate trajectories and clinical prognosis, specifically 28-day mortality, among high-risk C-K-M-sepsis patients and across various subgroups. METHODS: We extracted data for high-risk C-K-M-Sepsis patients from the MIMIC-IV database. After developing a simplified C-K-M staging system, we used unsupervised consensus clustering to identify four metabolic phenotypes. Serum phosphate trajectories during the first seven ICU days were summarized by daily earliest measurements. Associations between phosphate trajectory clusters and 28-day ICU mortality were examined using multivariable logistic regression, inverse probability weighting (IPW) derived from propensity scores, and doubly robust estimation. Subgroup analyses stratified by age, sex, and key comorbidities were conducted, and results were visualized as forest plots. RESULTS: Multivariate analysis revealed that trajectory Group 3 (persistently high serum phosphate) had significantly increased mortality risk (OR=2.909, 95% CI: 2.121-2.991, p < 0.001). Elevated risk was prominent in younger (<65 years) and male subgroups. Comorbidity analysis identified CVA and COPD as significant risk factors. CONCLUSION: Serum phosphate trajectory patterns significantly correlate with 28-day mortality in high-risk CKM-sepsis patients, highlighting potential distinct metabolic phenotypes. Early intervention targeting serum phosphate levels may improve prognosis in high-risk subgroups.